Clinical Trial Update: Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM [Phase 3]

View source ↗

Summary

Phase 3 study evaluating ASC40 tablets in combination with bevacizumab for recurrent glioblastoma; the trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• ASC40
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Ascletis Pharmaceuticals Co., Ltd. | Conditions: Recurrent Glioblastoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING